Stockreport

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sé [Read more]